Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials

We evaluated the changes in heart rate on the treatment with SGLT2 inhibitor, luseogliflozin, in Japanese patients with type 2 diabetes mellitus (T2DM). It is suggested that luseogliflozin can effectively decrease in heart rate in patients with higher baseline.[Image: see text]

Detalles Bibliográficos
Autores principales: Sano, Motoaki, Chen, Shi, Imazeki, Hisae, Ochiai, Hidekazu, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934252/
https://www.ncbi.nlm.nih.gov/pubmed/29750107
http://dx.doi.org/10.1111/jdi.12726
_version_ 1783320082933350400
author Sano, Motoaki
Chen, Shi
Imazeki, Hisae
Ochiai, Hidekazu
Seino, Yutaka
author_facet Sano, Motoaki
Chen, Shi
Imazeki, Hisae
Ochiai, Hidekazu
Seino, Yutaka
author_sort Sano, Motoaki
collection PubMed
description We evaluated the changes in heart rate on the treatment with SGLT2 inhibitor, luseogliflozin, in Japanese patients with type 2 diabetes mellitus (T2DM). It is suggested that luseogliflozin can effectively decrease in heart rate in patients with higher baseline.[Image: see text]
format Online
Article
Text
id pubmed-5934252
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59342522018-05-10 Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials Sano, Motoaki Chen, Shi Imazeki, Hisae Ochiai, Hidekazu Seino, Yutaka J Diabetes Investig Letters to the Editor We evaluated the changes in heart rate on the treatment with SGLT2 inhibitor, luseogliflozin, in Japanese patients with type 2 diabetes mellitus (T2DM). It is suggested that luseogliflozin can effectively decrease in heart rate in patients with higher baseline.[Image: see text] John Wiley and Sons Inc. 2018-05-03 2018-05 /pmc/articles/PMC5934252/ /pubmed/29750107 http://dx.doi.org/10.1111/jdi.12726 Text en © 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Letters to the Editor
Sano, Motoaki
Chen, Shi
Imazeki, Hisae
Ochiai, Hidekazu
Seino, Yutaka
Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials
title Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials
title_full Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials
title_fullStr Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials
title_full_unstemmed Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials
title_short Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials
title_sort changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: subanalysis of placebo‐controlled, double‐blind clinical trials
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934252/
https://www.ncbi.nlm.nih.gov/pubmed/29750107
http://dx.doi.org/10.1111/jdi.12726
work_keys_str_mv AT sanomotoaki changesinheartrateinpatientswithtype2diabetesmellitusaftertreatmentwithluseogliflozinsubanalysisofplacebocontrolleddoubleblindclinicaltrials
AT chenshi changesinheartrateinpatientswithtype2diabetesmellitusaftertreatmentwithluseogliflozinsubanalysisofplacebocontrolleddoubleblindclinicaltrials
AT imazekihisae changesinheartrateinpatientswithtype2diabetesmellitusaftertreatmentwithluseogliflozinsubanalysisofplacebocontrolleddoubleblindclinicaltrials
AT ochiaihidekazu changesinheartrateinpatientswithtype2diabetesmellitusaftertreatmentwithluseogliflozinsubanalysisofplacebocontrolleddoubleblindclinicaltrials
AT seinoyutaka changesinheartrateinpatientswithtype2diabetesmellitusaftertreatmentwithluseogliflozinsubanalysisofplacebocontrolleddoubleblindclinicaltrials

Ejemplares similares